XEMBIFY (Grifols Australia Pty Ltd)
Product name
XEMBIFY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
143 (255 working days)
Active ingredients
human immunoglobulin G
Registration type
NCE/NBE
Indication
Indications for subcutaneous administration (SCIg)
XEMBIFY (solution for subcutaneous injection) is indicated as replacement therapy in adult and paediatric patients for: